TAK-875/Fasiglifam (Takeda): phase I/II trials showed reduced blood glucose levels, increased insulin levels, 1.2–1.4% reduction in HbA1c levels with no associated weight gain/hypoglycemia in T2D patients. Removed from phase III trials due to potential liver toxicityAMG-837 (Amgen) and LY2881835 (Eli Lilly): removed from phase I trials due to toxicityJTT-851 (Japan Tobacco): currently in phase II trialsP11187 (Piramal): currently in phase I trials. This evidence concerns the gene INS and Hypoglycemia.